Source: Congenital heart disease. Unidade: FM
Subjects: CARDIOPATIAS CONGÊNITAS, HIPERTENSÃO PULMONAR, INIBIDORES DE ENZIMAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CLAVE, Mariana M et al. Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease. Congenital heart disease, v. 14, n. 2, p. 246-255, 2019Tradução . . Disponível em: https://doi.org/10.1111/chd.12688. Acesso em: 28 abr. 2024.APA
Clave, M. M., Maeda, N. Y., Thomaz, A. M., Bydlowski, S. P., & Lopes, A. A. (2019). Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease. Congenital heart disease, 14( 2), 246-255. doi:10.1111/chd.12688NLM
Clave MM, Maeda NY, Thomaz AM, Bydlowski SP, Lopes AA. Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease [Internet]. Congenital heart disease. 2019 ; 14( 2): 246-255.[citado 2024 abr. 28 ] Available from: https://doi.org/10.1111/chd.12688Vancouver
Clave MM, Maeda NY, Thomaz AM, Bydlowski SP, Lopes AA. Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease [Internet]. Congenital heart disease. 2019 ; 14( 2): 246-255.[citado 2024 abr. 28 ] Available from: https://doi.org/10.1111/chd.12688
